Disclosed herein are serine threonine kinase (AKT) degradation/disruption compounds including an AKT ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of AKT-mediated diseases.

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure

##STR00001##

and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and R.sup.2 are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-β superfamily, and can be used to treat disease by blocking such activity.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:

##STR00001## or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Disclosed herein are otic formulations and compositions comprising growth factors. These otic formulations and compositions allow for the delivery of the growth factor to the outer, middle, and/or inner ear for the treatment of otic diseases and disorders.

Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprising the first parent IgG class Fc-region polypeptide of a) and the second parent IgG class Fc-region polypeptide of a).

The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein having specific glycosylation patterns. The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein made from CHO cells. The present disclosure also relates to methods for the use of these proteins.

A composition used for combating metabolic diseases and uses of (or a method for) the composition. The pharmaceutical composition comprises therapeutic agent A or a pharmaceutically acceptable salt thereof; therapeutic agent B or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable excipient, where therapeutic agent A is a non-steroidal anti-inflammatory medicament, and therapeutic agent B is a fatty acid oxidation inhibitor. The pharmaceutical composition effectively treats or prevents obesity, non-alcoholic fatty liver, polycystic ovary syndrome, type 2 diabetes, and metabolic syndrome diseases caused by insulin resistance.

The invention provides a method for the production of a zeolite particle composition which has optimized characteristics, such as enhanced adsorption and specific ion exchange properties. A method and an apparatus for producing improved zeolite particle compositions are provided, where the particles are treated with an oxygen-containing gas during micronisation. The zeolite particle compositions can be used in a method for treatment of the human or animal body by therapy and/or prophylaxis, and specifically in a method of treating or preventing conditions of the human or animal body or symptoms of these conditions that are related to heavy metals, endotoxins, exotoxins, and/or bacterial, viral or parasitic intoxications in or of the digestive system, mucosal surfaces or the skin. Also, new zeolite particle compositions can be used as food additive, as filter for purification of water, in packaging materials, or as cosmetic ingredient.

The present invention relates to a bifunctional angiogenesis inhibitor, which has VEGF inhibitory activity and FGF inhibitory activity, and can inhibit VEGF and FGF dual factors-induced or high glucose-induced cell proliferation, cell migration, and/or lumen formation. The present invention also relates to the use of the bifunctional angiogenesis inhibitor in inhibiting retinal angiogenesis, such as diabetic retinopathy, age-related macular degeneration and the like.

Disclosed are a benzonitric heterocyclic compound, a preparation method therefor and the use thereof. Provided in the present invention is a benzonitric heterocyclic compound represented by formula I, or a pharmaceutically acceptable salt thereof, which can be used as a histone deacetylase inhibitor, has a selective inhibitory effect on HDAC6, and has characteristics such as a high efficiency, low toxicity and ideal pharmacokinetic properties.

##STR00001##